As many biotechnology companies struggle to progress pipelines and deal with product setbacks in the face of dwindling cash reserves, Europe's vaccines plays are navigating today's difficult waters more successfully.
Vaccine companies, the perennial middle child of the life sciences, have increased margins on their products, consolidated effectively, jettisoned dead...